CEO Appointed to Spearhead Transition Stage

MISSION Therapeutics, a company focused on modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer and other diseases, has appointed Dr Anker Lundemose MD PhD as Chief Executive Officer at a pivotal stage in the Company’s evolution, as it transitions from discovery to development. Most recently CEO of Norwegian vaccine company Bionor Pharma ASA and previously co-founder and CEO of Prosidion, the UK spin-out of OSI Pharmaceuticals’ diabetes and obesity assets, the move constitutes Dr Lundemose’s fourth CEO position. He has been involved in a total of six biotech exits/IPOs.

Michael Moore, MISSION Executive Chairman, commented: “On behalf of the board and management I am delighted to welcome Anker at this exciting time for the Company, as it embarks on the preclinical development of its lead molecules. His extensive drug translational and business development experience across several therapeutic areas, among his other corporate credentials, will catalyze our transition from discovery to development and maximise the commercial horizons of the Company.”

Anker Lundemose commented: “I am thrilled to be joining MISSION at this transitional stage of the Company’s development.  MISSION clearly has the opportunity to become the world’s premier DUB R&D company given the world-class standing of its science, the track record of its management and the vision of its investor syndicate. I look forward to working with management and investors alike to build on the asset value already created by the MISSION team.”